The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health
Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic, the exclusive licensee of the ABNCoV2 COVID-19 vaccine, will receive up to DKK 800 million in funding from the Danish Ministry of Health for a Phase III trial to confirm safety and demonstrate efficacy as a booster vaccine, the experimental development of the necessary production processes, and the works related to the required regulatory authorisations.This important milestone means that Bavarian Nordic now has a strong financial